Pharmacological inhibition of HMGB1 by CDK4/6 inhibitors has been also shown to present a powerful tool to overcome breast cancer resistance to tamoxifen by disrupting the TLR4-NF-κB pathway [244]. Here, HMGB1 is linked to breast carcinoma.